Affilogic is a private biotech company specialized in discovering and developing Nanofitins^®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

Recent news :

Apr 2025 – Affilogic’s Partner Bracco Imaging published Nanofitins data in Nature Scientific Report  : Bracco Imaging has published new data using HER-2 targeting Nanofitins used as diagnostic tool for the management of HER-2 positive tumors.

Mar 2025 – Affilogic’s new publication in Biomolecules  : Jacquot & al. – A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice